Human endogenous retroviruses (HERVs) are attracting increasing attention having been linked to numerous diseases, including autoimmunity, and in particular multiple sclerosis (MS). 1 Approximately 8% of our genome is made up of retroviral sequences, with the majority of these sequences being related to HERVs. 2 HERVs entered our genomes via germ-line infection during evolution and are generally present at unique chromosomal locations; 2 however HERVs may have unfixed, or new, locations should an individual be newly infected or re-infected. 3 It should be noted, however, that whereas the infectivity of endogenous retroviruses from other species has been demonstrated, the infectivity of HERVs has yet to be unequivocally shown.
Some HERVs remain active, and competent, and therefore can be activated and theoretically reintegrate into the genome. 4 As reintegration events are semi-random they may result in altered regulation of the genome, which could result in tumorigenesis or affect immunological function and theoretically trigger autoimmunity. 1 Proviruses can be distinguished by flanking sequences from their host, which may allow one to recognise their integration or genomic location. 4 HERVs can and do express proteins even if they are replication incompetent, i.e. incapable of reintegration, or remain episomal. These proteins can have biological effects, for example syncytin-1 from HERV-W is expressed in placental cells and results in formation of syncytia and hence placenta formation. 5 The locus encoding syncytin is named ERVWE1, 6 which is part of the HERV-W/7q proviral copy. 7 Transcripts and proteins from HERV genes have been detected in the central nervous system, particularly in relation to inflammation. 1 Multiple sclerosis retrovirus (MSRV), a HERV-W-related retroelement, has been associated with MS and several psychiatric disorders. MSRV has been reported to be a biomarker in MS and a possible immunological effector of the autoimmune response.
In this issue Perron and co-authors reproduce their previous work 8 in which they identify MSRV from other HERV-W sequences and quantified the abundance of specific HERV-W env sequences using real-time PCR in samples from people with MS and controls. 9 The authors do not discuss their findings in the context of published results, which have been discussed by others, that ERVWE1 envencoding DNA detection (p < 0.05) and RNA expression (p < 0.01) were increased in the brains of MS patients while comparable changes in MSRV abundance were not observed 10 and that no differences were observed between clinical groups when peripheral blood mononuclear cell (PBMC) derived DNA was examined for ERVWE1 and MSRV. 10 Whilst ERVWE1, encompassing one complete open reading frame for Env, 4 is identified as being from the HERV-W family, it remains unclear what the nature of MSRV actually is. MSRV is mainly known as virionassociated RNA identified by RT-PCR. [11] [12] [13] [14] No specific MSRV locus has been identified in the human genome. The ambiguous use of various classifications of the involved proteins or RNAs as "MSRV-type" HERV-W, as "MSRV/HERV-W", or as "HERV-W pathogenic subtype MSRV" may explain why a specific locus for MSRV has yet to be identified.
The authors have not explicitly stated that there is evidence of HERV-W (or MSRV) replication or infectivity, but the results expressed in Figure 8 imply "potential chromosomal retro-insertion" and "virion uptake in neighboring or distant macrophage and microglial cells". 9 Apart from the observed accumulation of DNA amplificates, Perron and colleagues have provided no data or sequences on novel chromosomal integration sites. 9 However, we acknowledge that a study of chromosomal reintegration sites would require single cell studies of positive cells; this is not a trivial task. Until this is done the question will remain whether or not there is a complete gamma-retroviral HERV locus in the human genome. Given the alignment trees of RNA and DNA sequences ( Fig. 4 and Fig. 5 ) it cannot be excluded that the sequences described may be PCRrelated phenomena. 9 Increased expression of the HERV-W envelope-encoded glycosylated protein has been seen within MS lesions. 15 Glial overexpression of syncytin-1 induces endoplasmic reticulum stress and the induction of free radicals. Syncytin-1 binds to ASCT1, a neutral amino acid trans-HERVs: have we been here before? porter expressed on glia, which is suppressed in the white matter from people with MS. 1 Antioxidants ameliorate the pathogenic effects of syncytin-1 raising the possibility of using these antioxidants as a therapy in MS. 1 In addition to HERV-W/MSRV, HERV-H and, to a lesser extent, HERV-K are also implicated in MS and other neurological diseases but further delineation of their contributions to disease are awaited. 16 HERV-K proteins have not been found in the brains from people with MS, 17 whereas HERV RNAs have been found to be elevated in MS brain lesions. 18, 19 One mechanism that has been proposed is that HERVs interact with herpes viruses; 16 an interaction between HERVs and EBV would be required to explain the strong association between EBV infection and MS, that many consider causative. 20 To address whether or not HERVs are involved in the pathogenesis of MS we recommend framing a set of welldefined questions in the context of Bradford-Hill's criteria for causation. 21 A cursory assessment indicates that a lot more basic research is required, including replicating the findings, to clarify the role of HERVs in the pathogenesis of MS. However, whether the role is causal or simply an association needs to be established and one way of pursuing this is with well-controlled clinical trials targeting HERV biology. For example, in a recent presentation at the 28 th ECTRIMS, in Lyon, Curtin and colleagues presented safety and pharmacokinetic data on a humanized monoclonal antibody against the MSRV envelope protein. 22 This protein, which activates a pro-inflammatory cascade through its interaction with Toll-Like receptor 4 (TLR4) on antigen-presenting cells, is a potential therapeutic target in MS. 22 The investigators also report on an ongoing clinical trial development programme in patients with MS. 22 We have clearly been here before, but the prospect of clinical trials in MS targeting HERV biology is a very exciting development. Let us hope that we will be pleasantly surprised by the results. Table 1 . Bradford-Hill's criteria for causation in relation to HERVs and MS. 21 Hill's Criteria 23 General question Interpretation 1
Consistency and unbiasedness of findings
Is there agreement amongst repeated observations in different places, at different times using different methodologies, by different researchers, under different circumstances?
At present the literature is not clear and the results have yet to be reproduced by independent groups.
2
Strength of association
What is the relative risk?
The assays used in this study need to be optimized and then used to establish, and confirm, in large population-based studies the strength of the association. 3
Temporal sequence At present the experimental evidence that HERVs are directly involved in the pathogenesis of MS is circumstantial. Clinical trials that target HERV either directly, or indirectly by neutralizing their biological products, which are thought to mediate some of the pathogenic effects, are feasible and should be explored.
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